AbbVie (NYSE: ABBV) has unveiled that RINVOQ® (upadacitinib) is now indicated in the U.S. for pediatric patients aged two and above suffering from active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA) if they have not responded well to one or more tumor necrosis factor (TNF) blockers. Additionally, a new weight-based oral solution, RINVOQ® LQ (upadacitinib), is now accessible for these pediatric populations.

"RINVOQ has been an important addition to the treatment landscape for various rheumatic diseases, helping adult patients achieve meaningful disease control," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. "AbbVie is proud to now offer RINVOQ as a tablet and oral solution to some of our youngest patients."

Highlights

• RINVOQ® (upadacitinib) now indicated for pediatric patients aged two and above with active pJIA and PsA
• New weight-based oral solution, RINVOQ® LQ (upadacitinib), available for pediatric populations

Understanding Juvenile Arthritis

Nearly 300,000 children and adolescents in the U.S. have juvenile idiopathic arthritis, including pJIA and PsA. The polyarticular form involves inflammation in five or more joints for at least six weeks before the age of 16, while PsA is characterized by joint inflammation and psoriasis-associated skin lesions.

Healthcare Community Insights

"Pediatric patients with pJIA and PsA can be severely limited in their ability to complete daily physical tasks and participate in everyday activities. Understanding their needs today and knowing the likelihood of disease in adulthood underscores the need for additional treatment options," said Aarat Patel, M.D., adult and pediatric rheumatology.

Data and Safety

The approvals of RINVOQ and RINVOQ LQ oral solution are supported by evidence from well-controlled studies, including data from pediatric patients with active polyarthritis. Safety considerations include potential serious side effects such as infections, increased risk of death in older individuals with heart disease risk factors, cancer risks, cardiovascular events, blood clots, and serious allergic reactions.

About RINVOQ® (upadacitinib)

RINVOQ, a JAK inhibitor, is being studied in various immune-mediated inflammatory diseases. Phase 3 trials in multiple conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, are ongoing.

Data source: https://news.abbvie.com/2024-06-04-RINVOQ-R-upadacitinib-Now-Available-for-Pediatric-Patients-Two-Years-and-Older-with-Polyarticular-Juvenile-Idiopathic-Arthritis-and-Psoriatic-Arthritis